微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 29.26% | 18.18% | 14.68% | 116/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 25.52% | -13.07% | -0.41% | 129/159 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 25.62% | -13.13% | 0.44% | 130/159 | 22.98% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 25.51% | -14.83% | 3.02% | 130/159 | 33.39% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 24.76% | -13.9% | -15.65% | 130/159 | 51.73% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 29.36% | 7.46% | -0.47% | 123/159 | 51.53% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 29.5% | 4.05% | -1.52% | 122/159 | 32.76% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 29.95% | 7.93% | 4.15% | 122/159 | 38.65% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 28.76% | 7.41% | 5.27% | 121/159 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 27.32% | -14.63% | -3.63% | 127/159 | 53.74% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 28.35% | -11.38% | 2.14% | 121/159 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 27.75% | -6.8% | 3.65% | 128/159 | 21.74% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 26.77% | -0.28% | -16.33% | 123/159 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 32% | 0.47% | 0.04% | 123/159 | 55.21% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 31.99% | -13.97% | 7.43% | 106/159 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 29.78% | -17.12% | 10.91% | 125/159 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 26.85% | -27.02% | -15.71% | 111/159 | 54.21% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 31.85% | -12% | -14.33% | 125/159 | -144.37% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 37.18% | 2.84% | 3.5% | 97/159 | 56.57% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 35.93% | 1.87% | -2.34% | 106/159 | 54.32% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 36.79% | 9.18% | 1.63% | 87/159 | 55.5% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 36.19% | 8.75% | 0.11% | 108/159 | -1213.38% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 36.15% | 9.53% | 2.52% | 87/159 | 55.47% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 35.27% | 3.29% | 4.67% | 92/159 | 55.47% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 33.69% | -0.75% | 1.24% | 89/159 | 51.37% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 33.28% | -7.55% | 0.82% | 108/159 | -205.91% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 33.01% | -10.67% | -3.32% | 86/159 | 54.25% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 34.14% | -10.11% | 0.58% | 86/159 | 53.68% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 33.95% | -10.85% | -5.71% | 81/159 | 54.19% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 36% | -15.6% | -2.58% | 89/159 | 52.58% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 36.95% | -14.58% | -2.71% | 68/159 | 49.32% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 37.98% | -15.68% | -0.25% | 70/159 | 48.02% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 38.08% | 2% | -10.74% | 55/159 | 46.89% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 42.66% | -4.07% | -1.39% | 64/159 | 48.44% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 43.26% | 2% | -3.97% | 39/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 45.05% | 2% | 1.3% | 43/159 | 46.2% | 微芯生物 | 97.46% | 行业排名> |
| 2015-12-31 | 44.47% | 10.23% | 10.23% | 49/159 | 46.24% | 贝达药业 | 97.01% | 行业排名> |